Published online Oct 10, 2015. doi: 10.5306/wjco.v6.i5.96
Peer-review started: February 2, 2015
First decision: April 27, 2015
Revised: June 8, 2015
Accepted: September 7, 2015
Article in press: September 8, 2015
Published online: October 10, 2015
Processing time: 257 Days and 3 Hours
Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas that present a poor prognosis. Personalized approaches are currely being developed and molecular targets are emerging from recent integrated genomic analyses. Targeted therapy will represent an important treatment option for TETs with an aggressive histology. To date, data indicate that vascular endothelial growth factor molecules, insulin-like growth factor 1 receptor, cyclin-dependent kinases and mammalian target of rapamycin may be potentially useful as targeted biological therapies.
Core tip: Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities. To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification. Targeted therapy will represent an important treatment option for TETs with an aggressive histology.
- Citation: Berardi R, Morgese F, Garassino MC, Cascinu S. New findings on thymic epithelial tumors: Something is changing. World J Clin Oncol 2015; 6(5): 96-98
- URL: https://www.wjgnet.com/2218-4333/full/v6/i5/96.htm
- DOI: https://dx.doi.org/10.5306/wjco.v6.i5.96
Thymic epithelial tumors (TETs) are uncommon neoplasms with a wide range of anatomical, clinical, histological and molecular malignant entities[1,2].
To date the management of TETs within clinical practice is based on a multimodal therapeutic strategy including surgery, chemotherapy and radiotherapy with a multidisciplinary approach and prognostic evaluation is mainly based on Masaoka staging and World Health Organization classification.
Therefore novel strategies are needed, especially for refractory and/or recurrent TETs and for thymic carcinomas (TC) that present a poor prognosis. Personalized approaches are currently being developed and molecular targets are emerging from recent integrated genomic analyses[3-5].
However where does research aim and what could we expect for the future in this setting?
We believe that targeted therapy will represent an important treatment option for TETs with an aggressive histology.
To date, data indicate that vascular endothelial growth factor molecules, insulin-like growth factor 1 receptor (IGF1R), cyclin-dependent kinases (CDK) and mammalian target of rapamycin may be potentially useful as targeted biological therapies.
In this regard, Thomas et al[6] in non-randomized phase II trial demonstrated efficacy of sunitinib in patients with pre-treated TC.
As IGF1R overexpression is a poor prognostic factor, Rajan et al[7] recently reported that Cituxumumab, an IGF1-R directed monoclonal antibody, could produce a promising 90% disease control rate in refractory thymomas.
Therefore, Besse et al[8] have initiated a single-arm Phase II study with Milciclib, an CDK inhibitor, in advanced TC/B3 thymomas based on good overall response rate, observed in a phase I study.
Also Zucali et al[9] conducted a single arm, single-stage, open label, multicentre phase II trial with everolimus in pre-treated TETs and TC patients. Out of 35 enrolled patients, 71.4% achieved disease control with a median PFS was 12.1 mo, while median OS was 24.0 mo.
The main aim of ongoing trials and new studies is to increase knowledge about etiology and genetic alterations involved in various types of TETs, leading to development and use of biological therapies that will be particularly useful for managing of refractory, recurrent tumors and for TC.
Additionally, STAT3 and PD-L1 protein expression level, both involved in bad prognosis, may have vital importance to evaluate the prognosis of TETs, especially precise for the highly malignant TETs.
In our opinion, further investigations on these genes could increase our knowledge about molecular mechanisms responsible for the TETS heterogeneity, about tumor interactions with adjacent healthy tissue and as regard its variegated response to treatments, to guarantee the development of new promising therapies[10,11].
P- Reviewer: Nishiyama M, Qi F, Todorova R S- Editor: Tian YL L- Editor: A E- Editor: Jiao XK
1. | Travis WD, Brambilla E, Muller-Hermelink HK and Harris CC. Pathology and genetics of tumors of the lung, pleura, thymus and heart. WHO Classification of Tumors. 2nd ed. Lyon: IARC Press 2004; 145-197. [Cited in This Article: ] |
2. | Ströbel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol. 2010;5:S286-S290. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 4.7] [Reference Citation Analysis (0)] |
3. | Girard N. Thymic epithelial tumours: from basic principles to individualised treatment strategies. Eur Respir Rev. 2013;22:75-87. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
4. | Berardi R, De Lisa M, Pagliaretta S, Onofri A, Morgese F, Savini A, Ballatore Z, Caramanti M, Santoni M, Mazzanti P. Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treat Rev. 2014;40:495-506. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
5. | Serpico D, Trama A, Haspinger ER, Agustoni F, Botta L, Berardi R, Palmieri G, Zucali P, Gallucci R, Broggini M. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Ann Oncol. 2015;26:838-847. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
6. | Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 2015;16:177-186. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 154] [Cited by in F6Publishing: 199] [Article Influence: 19.9] [Reference Citation Analysis (0)] |
7. | Rajan A, Carter CA, Berman A, Cao L, Kelly RJ, Thomas A, Khozin S, Chavez AL, Bergagnini I, Scepura B. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15:191-200. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 80] [Cited by in F6Publishing: 98] [Article Influence: 8.9] [Reference Citation Analysis (0)] |
8. | Besse B, Garassino MC, Rajan A, Novello S, Mazieres J, Weiss GJ, Ciomei M, Martignoni M, Petroccione A, Davite C. A phase II study of milciclib (PHA- 848125AC) in patients (pts with thymic carcinoma (TC). J Clin Oncol. 2014;32:abstr 7526. [Cited in This Article: ] |
9. | Zucali PA, De Pas TM, Palmieri G, Favaretto AG, Chella A, Tiseo M, Caruso M, Perrino M, De Vincenzo F, Simonelli M. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol. 2014;32:abstr 7527. [Cited in This Article: ] |
10. | Li C, Wang Z, Liu Y, Wang P, Zhang R. STAT3 expression correlates with prognosis of thymic epithelial tumors. J Cardiothorac Surg. 2013;8:92. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
11. | Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015;10:500-508. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: 88] [Cited by in F6Publishing: 110] [Article Influence: 12.2] [Reference Citation Analysis (0)] |